On January 25, 2023 ArcticZymes Technologies, reported that the Company will host a Q4 2022 presentation, followed by an extended investor presentation for investors, analysts and media at 08:30 CET on Thursday, 02 February 2023 at Høyres Hus, Stortingsgata 20, Oslo (Press release, Biotec Pharmacon, JAN 25, 2023, View Source [SID1234626539]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be given by the Chairman of the board, Marie Roskrow, CFO Børge Sørvoll, VP Business Development and Marketing, Dirk Hahneiser, VP of Operations Marit Sjo Lorentzen and CSO Darren Ellis. CEO Jethro Holter is currently on sick leave and will not participate.

The presentation can also be followed as a live webcast from Hegnar TV on www.arcticzymes.com or https://channel.royalcast.com/landingpage/hegnarmedia/20230202_2/. It will be possible to post questions through the webcast console.

The report for the fourth quarter 2022 and the extended investor presentation will be available on www.newsweb.no and on the company’s homepage www.arcticzymes.com from 07.00 CET on Thursday, 02. February 2023.